miR-129 regulates cell proliferation by downregulating Cdk6 expression

Junjie Wu1, Jun Qian, Chun Li

  • 1Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA, USA. jining@bu.edu

Insights

MicroRNA-129 (miR-129) inhibits tumor cell proliferation by targeting Cdk6, a key regulator of the G1/S phase transition. Overexpression of miR-129 induces cell cycle arrest and death, highlighting its tumor-suppressive role.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • Reduced microRNA-129 (miR-129) expression is observed in various cancers, including lung adenocarcinoma.
  • miR-129 exhibits anti-proliferative activity in tumor cell lines, but its regulatory mechanisms remain unclear.

Purpose of the Study:

  • To investigate the role of miR-129 in regulating cell proliferation.
  • To identify the molecular targets of miR-129 involved in cell cycle control.

Main Methods:

  • Lentiviral-mediated overexpression of miR-129 in mouse lung epithelial cells (E10) and human lung adenocarcinoma cell lines.
  • Cell cycle analysis (G1 phase arrest).
  • Target validation using luciferase reporter assays and Western blotting to assess Cdk6, Erk1, Erk2, and Prkce expression.

Main Results:

  • Overexpression of miR-129 induced significant G1 phase arrest and cell death in lung epithelial and adenocarcinoma cells.
  • Cyclin-dependent kinase 6 (Cdk6) was identified as a direct target of miR-129.
  • Restoring Cdk6 expression partially rescued the cell growth arrest and cell death phenotypes.

Conclusions:

  • miR-129 functions as a tumor suppressor by inhibiting cell proliferation.
  • The primary mechanism involves the downregulation of its direct target, Cdk6, leading to G1 phase arrest.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.